Drug notes:
UB-311 Clin2 Alzheimer's; UB-312 Clin1 Parkinson's, DLB, MSA; UB-313 Clin1 migraine; VXX-401 Clin1 hypercholesterolemia; undisclosed RD/Clin0 Alzheimer's, undisclosed
About:
Vaxxinity is a pioneering biotechnology company dedicated to advancing vaccine development through innovative scientific approaches. Leveraging state-of-the-art molecular biology and immunology techniques, Vaxxinity focuses on designing next-generation vaccines that target chronic diseases, which are currently expensive treatments with less than 1% of the global population. Their scientific endeavors emphasize the use of novel antigen design, adjuvant technologies, and vaccine delivery systems to enhance efficacy, safety, and scalability. With a commitment to rigorous research and clinical validation, Vaxxinity aims to contribute significantly to public health by addressing current and emerging infectious and chronic threats with affordable treatments.